Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.

2.50
Hdl Handle:
http://hdl.handle.net/10541/71931
Title:
Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.
Authors:
Foster, C; Watson, M; Eeles, Rosalind; Eccles, Diana; Ashley, Sue; Davidson, R; Mackay, J; Morrison, P J; Hopwood, Penelope; Evans, D Gareth R
Abstract:
This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian cancer predisposition in a clinical cohort. Areas evaluated include risk management, distress and insurance problems 3 years post-testing. Participants are adults unaffected with cancer from families with a known BRCA1/2 mutation. One hundred and ninety-three out of 285 (70% response) participants at nine UK clinical genetics centres completed assessments at 3 years: 80% female; 37% carriers of a BRCA1/2 mutation. In the 3 years, post-genetic testing carriers reported more risk management activities than non-carriers. Fifty-five per cent of female carriers opted for risk reducing surgery; 43% oophorectomy; and 34% mastectomy. Eighty-nine per cent had mammograms compared with 47% non-carriers. Thirty-six per cent non-carriers > or =50 years did not have a mammogram post-test. Twenty-two per cent male carriers had colorectal and 44% prostate screening compared with 5 and 19% non-carriers respectively. Seven per cent carriers and 1% non-carriers developed cancer. Distress levels did not differ in carriers and non-carriers at 3-year follow-up. Forty per cent of female carriers reported difficulties with life and/or health insurance. Given the return to pre-test levels of concern among female non-carriers at 3 years and a substantial minority not engaging in recommended screening, there appears to be a need to help some women understand the meaning of their genetic status.
Affiliation:
Macmillan Research Unit, School of Nursing and Midwifery, University of Southampton, Southampton, UK.
Citation:
Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. 2007, 96 (5):718-24 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
12-Mar-2007
URI:
http://hdl.handle.net/10541/71931
DOI:
10.1038/sj.bjc.6603610
PubMed ID:
17285126
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorFoster, C-
dc.contributor.authorWatson, M-
dc.contributor.authorEeles, Rosalind-
dc.contributor.authorEccles, Diana-
dc.contributor.authorAshley, Sue-
dc.contributor.authorDavidson, R-
dc.contributor.authorMackay, J-
dc.contributor.authorMorrison, P J-
dc.contributor.authorHopwood, Penelope-
dc.contributor.authorEvans, D Gareth R-
dc.date.accessioned2009-06-30T12:27:31Z-
dc.date.available2009-06-30T12:27:31Z-
dc.date.issued2007-03-12-
dc.identifier.citationPredictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. 2007, 96 (5):718-24 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid17285126-
dc.identifier.doi10.1038/sj.bjc.6603610-
dc.identifier.urihttp://hdl.handle.net/10541/71931-
dc.description.abstractThis prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian cancer predisposition in a clinical cohort. Areas evaluated include risk management, distress and insurance problems 3 years post-testing. Participants are adults unaffected with cancer from families with a known BRCA1/2 mutation. One hundred and ninety-three out of 285 (70% response) participants at nine UK clinical genetics centres completed assessments at 3 years: 80% female; 37% carriers of a BRCA1/2 mutation. In the 3 years, post-genetic testing carriers reported more risk management activities than non-carriers. Fifty-five per cent of female carriers opted for risk reducing surgery; 43% oophorectomy; and 34% mastectomy. Eighty-nine per cent had mammograms compared with 47% non-carriers. Thirty-six per cent non-carriers > or =50 years did not have a mammogram post-test. Twenty-two per cent male carriers had colorectal and 44% prostate screening compared with 5 and 19% non-carriers respectively. Seven per cent carriers and 1% non-carriers developed cancer. Distress levels did not differ in carriers and non-carriers at 3-year follow-up. Forty per cent of female carriers reported difficulties with life and/or health insurance. Given the return to pre-test levels of concern among female non-carriers at 3 years and a substantial minority not engaging in recommended screening, there appears to be a need to help some women understand the meaning of their genetic status.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOvarian Canceren
dc.subjectProstate Canceren
dc.subject.meshAdult-
dc.subject.meshBreast Neoplasms-
dc.subject.meshFemale-
dc.subject.meshGenes, BRCA1-
dc.subject.meshGenes, BRCA2-
dc.subject.meshGenetic Predisposition to Disease-
dc.subject.meshGenetic Screening-
dc.subject.meshGreat Britain-
dc.subject.meshHeterozygote-
dc.subject.meshHumans-
dc.subject.meshInsurance Selection Bias-
dc.subject.meshMale-
dc.subject.meshMammography-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshOvariectomy-
dc.subject.meshPatient Compliance-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshRisk Management-
dc.titlePredictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.en
dc.typeArticleen
dc.contributor.departmentMacmillan Research Unit, School of Nursing and Midwifery, University of Southampton, Southampton, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.